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Malaria during pregnancy, particularly Plasmodium falciparum malaria, has been linked to increased morbidity and
mortality, which must be reduced by both preventive measures and effective case management. The World Health
Organization (WHO) recommends artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum
malaria during the second and third trimesters of pregnancy, and quinine plus clindamycin during the first
trimester. However, the national policies of many African countries currently recommend quinine throughout
pregnancy. Therefore, the aim of this article is to provide a summary of the available data on the safety and efficacy
of artemether-lumefantrine (AL) in pregnancy. An English-language search identified 16 publications from 1989 to
October 2011 with reports of artemether or AL exposure in pregnancy, including randomized clinical trials,
observational studies and systematic reviews. Overall, there were 1,103 reports of AL use in pregnant women: 890
second/third trimester exposures; 212 first trimester exposures; and one case where the trimester of exposure was
not reported. In the second and third trimesters, AL was not associated with increased adverse pregnancy
outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to
quinine, and its efficacy was non-inferior to quinine. There is evidence to suggest that the pharmacokinetics of anti-
malarial drugs may change in pregnancy, although the impact on efficacy and safety needs to be studied further,
especially since the majority of studies report high cure rates and adequate tolerability. As there are fewer reports of
AL safety in the first trimester, additional data are required to assess the potential to use AL in the first trimester.
Though the available safety and efficacy data support the use of AL in the second and third trimesters, there is still
a need for further information. These findings reinforce the WHO recommendation to treat uncomplicated
falciparum malaria with quinine plus clindamycin in early pregnancy and ACT in later pregnancy.
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As pregnant women are at increased risk of malaria it is es-
sential to ensure that preventive measures, accurate diagno-
sis and effective treatments are accessible to this vulnerable
group [1]. Although all Plasmodium species can affect
maternal and foetal health, Plasmodium falciparum infec-
tion is associated with the most severe effects and has been
linked to increased maternal, foetal and neonatal morbidity
and mortality [1-3]. In 2007, an estimated 85.3 million* Correspondence: cmanyando@yahoo.com
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reproduction in any medium, provided the orpregnancies occurred in regions of P. falciparum transmis-
sion worldwide. Of these, the majority occurred in the
African (30 million), South East Asian and Western Pacific
(44.2 million) regions. Within the African region, 29.6
million pregnancies occurred in areas of stable transmission
and 0.4 million pregnancies occurred in areas of unstable
transmission [4]. In sub-Saharan Africa, where both malaria
and HIV are prevalent, the population-attributable fraction
of malaria cases due to HIV during pregnancy was
estimated at 4.8%, corresponding to an additional 505,382
pregnant women with malaria each year [5].tral Ltd. This is an Open Access article distributed under the terms of the Creative
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exposure to malaria parasites leads to the development of
partial immunity, and malaria infection is often asymp-
tomatic or without specific symptoms. Nevertheless,
malaria infection is associated with severe maternal an-
aemia, placental malaria and low birth weight – a risk fac-
tor for infant death [6,7]. Endemic malaria has been
associated with increased perinatal and foetal mortality,
risk of abortion, and premature delivery [1,2]. In areas of
unstable transmission where adults are unlikely to have
acquired immunity against malaria, pregnant women are
at increased risk of severe malaria, which can cause
maternal and foetal death [1,6]. In a hospital study in
Mozambique, maternal death from severe malaria was
more frequent in urban (12.5%) and suburban (14.3%)
areas where transmission was low as compared to rural
areas with moderate or stable transmission (3.6%) [3]. In a
large study of 1,030 pregnant women in Mozambique,
acute placental infection and parasitaemia in cord blood
were significantly associated with infant death, while ma-
ternal clinical falciparum malaria and acute placental in-
fection were associated with clinical malaria during
infancy [8].
The World Health Organization (WHO) recommends
the use of preventive measures to limit the occurrence of
malaria in pregnancy, including the use of insecticide-
treated nets and intermittent preventive treatment in
pregnancy (IPTp) in areas of stable malaria transmission.
The WHO also recommends that all cases of malaria
during pregnancy should be treated promptly with an
effective anti-malarial [6,9].
ACT in pregnancy
Artemisinin-based combination therapy (ACT) is effect-
ive and well tolerated in the general population and, if
shown to be safe and effective, may significantly reduce
morbidity and mortality during pregnancy [10]. Hence,
following 1,500 documented pregnancies exposed to
artemisinin derivatives during the second or third tri-
mester, the WHO assessed the benefits and potential risks
and recommended the use of ACT as a first-line treatment
for uncomplicated P. falciparum malaria during the
second and third trimesters [11]. Those recommended are
artemether-lumefantrine (AL), artesunate-amodiaquine
(AS-AQ), artesunate-mefloquine (AS-MQ) and artesu-
nate + sulphadoxine-pyrimethamine (AS+SP), but do not
include dihydroartemisinin-piperaquine (DHA-PPQ) due
to the lack of data in the second and third trimesters in
2010, when the latest edition of the WHO guidelines was
published [11].
ACT is not recommended by the WHO as a first-line
treatment during the first trimester, due to limited clinical
safety data [11] and evidence of embryo lethality and de-
velopmental abnormalities in animal studies followingartemisinin exposure early in pregnancy, at times equiva-
lent to the first trimester in humans [12,13]. The WHO
recommends a seven-day course of quinine plus clindamy-
cin (or quinine monotherapy if clindamycin is not avail-
able) as the first-line malaria treatment during the first
trimester of pregnancy, and artesunate plus clindamycin as
second-line treatment. ACT in the first trimester of preg-
nancy is indicated only if the recommended treatments
are not available or have failed [11].
It is vital that pregnant women with malaria receive
prompt and effective treatment [11]. However, the fre-
quent exclusion of pregnant women from pharmaceutical
trials, including the original studies of artemisinins and
different types of ACT, has limited the availability of data
in this vulnerable population. Consequently, ACT safety
and efficacy, including potential effects of changes in ACT
pharmacokinetics during pregnancy, is an important area
of malaria research with implications for national malaria
control policies. An understanding of the risks and bene-
fits of ACT during early and later pregnancy is needed to
guide policymakers and health-care workers, and ensure
that pregnant women receive both effective and safe treat-
ment against malaria.
The aim of this review is to discuss the available data
on the maternal and foetal safety, pharmacokinetics, and
anti-malarial efficacy of AL during pregnancy. As the
first fixed-dose ACT, AL has now been available for over
ten years and has been widely used as a first-line anti-
malarial in many countries worldwide, including sub-
Saharan Africa. Hence, there is a growing body of data
on the safety and efficacy of AL in pregnant women.
Methods
A literature search was performed to identify publications
that included specific reports of artemether or AL exposure
during human pregnancy and any safety, efficacy or phar-
macokinetic outcome. This included original research
studies and systematic reviews published in any year. The
search was limited to English-language publications. Ovid
was used to search EMBASE, Medline, Biosis and the
Cochrane database (16 December, 2011) according to the
search strategy shown in Additional file 1. The Malaria in
Pregnancy consortium library was searched using the
following sets of search terms (8 December, 2011): arte-
mether AND pregnancy; artemether-lumefantrine AND
pregnancy; lumefantrine AND pregnancy; artemisinins
AND pregnancy; ACT AND pregnancy AND malaria; ACT
AND pregnancy AND Plasmodium falciparum. The same
terms were used to search Clinicaltrials.gov (8 December,
2011) and the WHO International Clinical Trials Registry
Platform (ICTRP) (8 December, 2011) to identify any
publications related to the identified clinical trials, and
TrialTrove 5 was searched (14 December, 2011) between
2008 and 2011 using the following search combinations:
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lumefantrine Cipla (Cipla is a manufacturer of AL) OR
lumefantrine OR artemisinins AND pregnancy OR preg-
nant; artemether+ lumefantrine OR artemether OR arte-
mether+ lumefantrine Cipla AND pregnancy OR pregnant
AND malaria OR Plasmodium falciparum. References of
identified manuscripts were searched for additional reports.
The manuscripts identified in the search were screened
manually based on their titles and (where available)
abstracts and if appropriate on the full text to identify those
that included reports of artemether or AL exposure and any
safety, efficacy, or pharmacokinetic outcomes in human
pregnancy. Previous systematic reviews that included
artemether in human pregnancy were also selected. As each
article used separate outcome measures, the safety (mater-
nal, foetal, and infant), efficacy and pharmacokinetic out-
comes of each report were recorded and included in the
review. The type of study, location, dates, and relevant study
protocols were also included to put the data in context and
to highlight limitations. The data from each study were con-
sidered separately.
Results
The database searches identified 948 records from the
publication search and 118 clinical trial records (Additional
file 2). After removal of duplicates, 400 records were
screened based on their titles and (where available) abstracts
(Additional file 3). Of these, 343 were judged not to feature
any data on the subject of artemether or AL safety, efficacy
or pharmacokinetics in human pregnancy and were
excluded. Of 57 full text articles assessed for eligibility, 39
articles were excluded as they did not include specific
reports of artemether or AL exposures during pregnancy
and two articles were excluded to avoid duplication of preg-
nancy exposures. Sixteen relevant articles were identified
(Figure 1). These were published between 1989 and
October 2011, and included specific reports of artemether
or AL exposure in pregnancy in either randomized clinical
trials or observational studies and also previous systematic
reviews (Additional file 4).
In total, these articles contain reports of 1,236 arte-
mether exposures during pregnancy, including 964 in the
second and third trimesters, 261 exposures in the first
trimester, and 11 where the timing of exposure was not
reported. Of these, 1,103 related to AL exposures, with
890 in the second and third trimesters, 212 in the first
trimester, and one case where the timing of exposure
was not reported (Additional file 4).
Studies assessing the safety of artemether and AL
during pregnancy
The safety of artemisinins in pregnancy has been investi-
gated in the second and third trimesters in randomized
clinical trials and throughout pregnancy in observationalstudies. A 2007 review of all artemisinin derivatives used in
pregnancy identified 14 studies, reporting a total of 945
pregnancies exposed to artemisinins (artesunate or arte-
mether): 123 in the first trimester and 822 in the second
and third trimesters. Five of these studies were randomized
clinical trials; nine were descriptive non-randomized studies.
Women were followed up to delivery, and 214 infants were
examined up to at least one year of age. Overall, these
studies did not identify any effect of artemisinins on serious
maternal adverse events, adverse birth outcomes or neuro-
logical development deficits in the infants [14].
Within the review by Dellicour et al. [14], a total of 86
pregnancies were exposed to artemether across four studies:
one in Nigeria, one in Sudan, one in Thailand, and one in
China (Tables 1 and 2, Additional file 4). In the Nigerian
study, 45 pregnant women with drug-resistant falciparum
malaria were treated with artemether alone or artemether
then mefloquine between 1994 and 1997. The treatments
were all administered in the second or third trimester of
pregnancy. All infants were normal at birth and showed
normal physical and neurological development for the
period of assessment, which varied between six and
36 months [15]. The study in Sudan was conducted be-
tween 1997 and 2001, and a total of 28 pregnant women
with chloroquine- and quinine-resistant falciparum malaria
were treated with intramuscular artemether. Only one
woman received artemether treatment during the first
trimester. In this study, there were no maternal deaths, mis-
carriages, stillbirths or reports of congenital abnormalities,
but there was one perinatal death following a pre-term
labour [16]. In the Thai study, 11 pregnant women with
acute falciparum malaria received artemether, either alone
or combined with mefloquine, artesunate, clindamycin, or
lumefantrine between 1992 and 2000 [17]. The paper by
McGready et al. [17] includes all of the artemether expo-
sures reported across three publications. To avoid duplica-
tion of pregnancy exposures, the other two reports have not
been included [18,19]. Nine women were available for
follow-up, and of these, seven delivered normal infants.
There was one miscarriage and one maternal death from se-
vere malaria and anaemia [17]. In the Chinese study, two
pregnant women with typical signs and symptoms of
malaria were treated with artemether in 1980. Both women
were in the second trimester of pregnancy, both delivered
at full term and both children showed normal growth and
development at five years [20].
Since the Dellicour review, seven studies have reported
on the safety of AL during pregnancy: four observational
studies and three open-label randomized studies (Tables 1
and 2, Additional file 4). These studies reported on the
tolerability of AL during pregnancy and the pregnancy
outcomes.
A large prospective cohort study comparing the safety
of AL and sulphadoxine-pyrimethamine (SP) throughout
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Figure 1 Flow diagram showing the number of records retrieved, screened and included in this review article. Records were identified by
searching publication and clinical trial databases. Duplicates were removed and the remaining records were screened based on their titles,
abstracts or clinical trial information. Based on this screen, records judged not to feature any data on the subject of artemether or AL safety,
efficacy or pharmacokinetics in human pregnancy were excluded. Of 57 full text articles assessed for eligibility, 39 articles were excluded as they
did not include specific reports of artemether or AL exposures during pregnancy and two articles were excluded to avoid duplication of
pregnancy exposures. Sixteen relevant articles were therefore identified and included in this review article *1948–2011; **English-language articles.
All years; †All years; ICTRP, International Clinical Trials Registry Platform.
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was the recommended treatment for uncomplicated
falciparum malaria in the second and third trimesters of
pregnancy at that time [26]. In total, 495 women had
received AL and 506 had received SP to treat the index
episode of malaria. Diagnosis was predominantly based
on clinical symptoms, and was unconfirmed by micros-
copy or rapid diagnostic test (RDT) in 85% of cases. As
women in Zambia were recommended to receive SP as
IPTp in the second and third trimesters, 412 women in
the AL group had also received SP, while only 13 women
in the SP group had also received AL. There were no
significant overall differences in the rates of maternal
mortality (AL, 0.2%; SP, 1.0%), neonatal mortality (AL, 2.3%;SP, 2.3%), stillbirth (AL, 1.8%; SP, 2.5%), miscarriage (AL,
1.4%; SP, 1.6%), low birth weight (AL, 9.0%; SP, 7.7%), birth
defects (AL, 1.8%; SP, 1.4% [including umbilical hernia: AL,
6.5%; SP, 4.1%]) and infant neurological development
between the AL and SP groups. Premature delivery was
slightly more frequent in the SP group than the AL group
(17.4% versus 14.1%, respectively) [26].
The Zambian study also assessed the pregnancy out-
comes according to the timing of the anti-malarial treat-
ment. Within the population, 156 women received AL in
the first trimester and 138 women received SP and/or
quinine in the first trimester. The rates of perinatal deaths
(stillbirths and neonatal deaths) were similar for women re-
ceiving AL or SP in the first trimester (4.4% AL, 3.9% SP
Table 1 Maternal and infant safety outcomes of artemether and lumefantrine use during pregnancy
Publication Drug (n) Trimester Maternal outcomes Infant outcomes
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Sangaré et al.,
2011 [27]
AL (260)o 53p 207
A artemether; AE adverse events; AL artemether-lumefantrine; AS artesunate; C clindamycin; IM intramuscular; MQ mefloquine; Q quinine; SAE serious adverse
event; SP sulphadoxine-pyrimethamine; *These 13 exposures are not included in the total count of exposures to AL in pregnant women as they were also included
in McGready, et al. 2008 [22]; a5 years; bphysical and neurodevelopment within normal limits (6–36 months); cdrug related; dsevere malaria and anaemia; e1 year;
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related to prematurity, 2 pneumonia, 1 sepsis, 1 diarrhoea, 1 suspected beriberi; jnumber reporting at least 1 AE; ksepsis following a caesarean section; lAL group
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1 undiagnosed illness; o260 reports of AL treatment for an episode of malaria; p26 received only AL in the 1st trimester.
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(0.8% AL, 2.5% SP and/or quinine [including umbilical
hernia: AL, 6.9%; SP, 6.6%]) and assessments of infant neu-
rodevelopment. However, there were seven miscarriages,
four with confounding factors (two women had multiple
malaria episodes, one had syphilis and one received AL
and concomitant salbutamol for a threatened miscarriage),
in women exposed to AL in the first trimester, and none
in the SP group. As a result, the authors recommended
further monitoring of ACT use in the first trimester [26].
Another recent observational study investigated the safety
of artemisinins in the first trimester of pregnancy in Sudan
between 2006 and 2008 [24]. In total, 62 women had
received artemisinins in the first trimester: 48 received
artemether injections, 11 received AS+SP, and three
received AL. Within this study population, there were no
maternal deaths and 60 infants were born at full term. No
congenital malformations were reported and all 60 infants
survived to the final one-year time-point. Two women who
had received artemether injections in the first trimestermiscarried while receiving a quinine infusion for a subse-
quent malaria attack (20 weeks and 22 weeks) [24].
A study of the pharmacokinetics of AL during pregnancy,
conducted in Thailand in 2004, also reported on the safety
of AL [21]. In total, 13 women in the second and third tri-
mesters of pregnancy received AL to treat recrudescent
falciparum malaria after seven days of supervised quinine
treatment. All were rapidly cured of their infection (median
parasite clearance time was two days). There were no
reports of serious adverse events and all 13 women
delivered live infants with no congenital abnormalities. Ten
infants were available for follow-up at one year and of these,
nine showed normal development and one showed severe
developmental delay [21].
The fourth observational study was a retrospective
survey of anti-malarial use for self-reported episodes of
malaria conducted in Uganda between 2008 and 2009
[27]. Women with a pregnancy in the previous 12 months
that reached at least the third trimester were included in
the study, while current pregnancies were excluded.
Table 2 Pregnancy outcomes of artemether and lumefantrine use during pregnancy
Publication Drug (n) Trimester Pregnancy outcomes
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A artemether; AL artemether-lumefantrine; AS artesunate; C clindamycin; MQ mefloquine; Q quinine; SP sulphadoxine-pyrimethamine; *These 13 exposures are not
included in the total count of exposures to AL in pregnant women as they were also included in McGready et al., 2008 [22]; a5 years; binfant died, 2nd–3rd trimester
exposure; cassociated with maternal urinary tract infection; dA group, associated with quinine infusion for further malaria attack; eAL group n= 495, AL exposure
504, SP group n = 506, SP/Q exposure n= 516; fincluding umbilical hernia; g2 multiple malaria episodes, 1 syphilis, 1 concomitant salbutamol and AL for threatened
abortion; h260 reports of AL treatment for an episode of malaria; i26 received only AL in the 1st trimester; jtotal study population.
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occurrence of miscarriages prior to the third trimester. Of
500 women, 334 reported 637 episodes of malaria in their
last pregnancy. In the first trimester, 53 of 134 malaria
episodes were treated with AL alone (26) or AL and other
anti-malarials (27). In the second and third trimesters, 207
of 503 malaria episodes were treated with AL alone (113)
or AL and other anti-malarials (94). Safety outcomes were
not reported by drug or exposure time, but over the 500
pregnancies there were seven stillbirths (1.4%) and 493 live
births (98.6%) [27].
The safety of AL and quinine was recently compared in
an open-label randomized non-inferiority trial in Uganda
[25]. In total, 304 women in the second or third trimester
of pregnancy with uncomplicated falciparum malaria were
treated with either a three-day course of AL (152) or a
seven-day course of quinine (152). No significant differ-
ences were evident between the groups in the frequency of
miscarriages (AL, 2.1%; quinine, 2.9%), stillbirths (AL,1.4%; quinine, 2.2%), early neonatal deaths (AL, 2.1%;
quinine 4.4%), malformations (AL, 2.1%; quinine, 1.5%),
prematurity (AL, 8.4%; quinine, 12.4%) and low birth
weight (AL, 10.2%; quinine 13.4%). Laboratory tests also
showed no clinically significant adverse events and no
substantial differences in alanine aminotransferase, biliru-
bin, creatinine, and full blood count between the groups.
However, in terms of maternal tolerability, fewer women
in the AL group than the quinine group reported at least
one adverse event (61.8% versus 93%, respectively).
Tinnitus, nausea, vomiting and anorexia were the most
commonly reported events in the quinine group, with
abdominal pain, headaches and influenza-like syndrome
most common in the AL group. There was also one ma-
ternal death in the quinine group from sepsis following a
caesarean section [25].
The safety of AL and artesunate in the second and
third trimesters of pregnancy were compared in an
open-label randomized study in Thailand between 2004
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randomized to treatment: 125 to AL and 128 to artesunate
(seven days). Birth outcomes were assessed and were similar
between the two treatment groups. There was one reported
miscarriage in the artesunate group and one stillbirth in
each treatment group. No significant differences were
detected between the treatment groups in the occurrence of
congenital abnormalities (AL, 2.6%; artesunate, 3.3%), pre-
maturity (AL, 2.6%; artesunate, 8.3%) and low birth weight
(AL, 14.1%; artesunate, 19.8%). The authors reported that
there were no differences between the groups in terms of
growth or developmental parameters at one year after birth,
but that there were significantly more deaths in the
artesunate group (6.7%) than the AL group (0.9%), although
these deaths were unlikely to be related to treatment.
Tolerability of the two treatments was similar, with only
one serious adverse event related to treatment (Day 2 in-
crease in parasitaemia in the AL group) and one maternal
death, which was not suspected to be related to the AL
treatment (haemorrhagic shock after a ruptured uterus).
Haematology and blood chemistry evaluations detected no
difference in the occurrence of abnormal values at Day 14
between the treatment groups, and paired ECG examina-
tions (baseline and 1 hour after treatment) showed no
clinically relevant abnormalities after AL treatment. The
only adverse event that differed between the treatment
groups was tinnitus, which was more frequent in the artesu-
nate group (AL, 0%; artesunate, 8.5%) [22].
A 2006 Ugandan open-label, randomized study com-
pared AL with chlorproguanil-dapsone in the second
and third trimesters of pregnancy for the treatment of
uncomplicated falciparum malaria [23]. Chlorproguanil-
dapsone has now been withdrawn, and so only the
results from the AL arm of the study will be discussed
[28]. This study reported the occurrence of maternal ad-
verse events, but did not report on pregnancy outcomes.
In total, 58 women were randomly assigned to AL treat-
ment. Liver and renal function tests remained normal
throughout the study and the frequency of adverse
events was low (palpitations (4), dizziness (1), drowsiness
(1) and generalized skin rash (1)) [23].
Studies assessing the efficacy of AL during
pregnancy
The efficacy of AL against uncomplicated falciparum
malaria during the second and third trimesters of pregnancy
was investigated in the three open-label randomized studies
described above (Table 3, Additional file 4). In the Ugandan
study that compared AL with quinine, 152 women with
positive blood smears were randomized to each treatment.
This study reported high efficacy of AL during pregnancy
and the non-inferiority of AL relative to quinine. The
PCR-corrected cure rates were similar both at Day 42 (AL,
99.3% (range 96.0–99.9); quinine, 97.6% (range 93.1–99.5))and at delivery (or Day 42 if later) (AL, 98.2% (range
93.5–99.7); quinine, 96.1% (range 90.2–98.9)) [25]. The
Ugandan study of AL versus chlorproguanil-dapsone,
where 58 pregnant women with clinical symptoms of
malaria and positive blood smears were randomized to
AL, also reported high efficacy of AL with a 28-day cure
rate of 100% for both treatments [23]. However, the Thai
study comparing AL and artesunate treatment in women
with positive blood smears (AL, 125 women; AS, 128
women) reported a cure rate of less than 95% for AL at Day
42 and for both treatments at delivery (or Day 42 if later).
In this study, both treatment groups had a median
(range) time to parasite clearance of 2 (1–5) days,
but the PCR-adjusted cure rate at Day 42 was 95.2%
(95% CI 91.5–97.1) for artesunate and 87.2% (95% CI
81.1–93.2) for AL, and at delivery (or Day 42 if later)
was 89.2% (95% CI 82.3–96.1) for artesunate and
82.0% (95% CI 74.8–89.3) for AL. Before delivery (or
Day 42 if later), there were 20 recrudescent infec-
tions with AL and 10 with artesunate [22].
Studies assessing the pharmacokinetics of AL
during pregnancy
It has been reported that the pharmacokinetics of anti-
malarial treatments may change during pregnancy [29,30].
There are several reports of the pharmacokinetics of AL
during pregnancy, but there are currently no published data
directly comparing the pharmacokinetics in pregnant and
non-pregnant women (Table 4). A study conducted in
Thailand in 2004 assessed the lumefantrine and artemether
exposure in a small number (13) of women in the second
or third trimester of pregnancy, who were still infected after
seven days of supervised quinine treatment. Results were
compared with those of a previous report from a small
cohort (17) of non-pregnant adult malaria patients [21]. All
13 pregnant women were cured rapidly, with parasite
clearance within one to three days. Although data sets were
relatively limited by the small number of patients, lumefan-
trine plasma concentration-time curves for pregnant and
non-pregnant patients were very similar within the first five
days after treatment (i.e. within the relevant therapeutic
window). Lumefantrine total exposure (Area Under the
Curve [AUC]) from 60 hours after treatment initiation
(after last dose) until time infinity (AUC60h!∞) was 237 μg/
ml.h (90% predicted range 75–576) in pregnant women
versus 251 μg/ml.h (90% predicted range 79–616) in non-
pregnant adults, thus differing overall by only 6% [21,31]. In
addition, the median lumefantrine Cmax of 7.34 μg/ml
reported in pregnant women in this study was well within
the range of values reported in non-pregnant female and
male patients in several other studies [31-33]. Artemether
exposure was also described as being reduced in this preg-
nant population study compared with previous reports from
non-pregnant adults (pregnant women, median AUC0!8h
Table 3 Efficacy outcomes of artemether–lumefantrine use during pregnancy





study of AL vs. AS
in the 2nd and 3rd
trimesters
AL (125) 2 (1–3) days† 2 (1–5) days† 87.2% (95% CI 81.1–93.2){
at Day 42.82.0% (95% CI
74.8–89.3){ at delivery
(or Day 42 if later)
AS (128) 1 (1–2) days† 2 (1–5) days† 95.2% (95% CI 91.5–97.1){
at Day 42.89.2% (95% CI
82.3–96.1){ at delivery





study of AL vs.
chlorproguanil-dapsone*
in the 2nd and 3rd
trimesters
AL (58) 47 (85.5%)
clear at Day 2
49 (89.1%)
clear at Day 2
100% at Day 28
Piola et al., 2010 [25] Ugandan study. Open-label,
randomized study of AL vs. Q
in the 2nd and 3rd trimesters
AL (152) 130 (100%)
clear at Day 2
148 (99%)




at delivery (or Day 42
if later)
Q (152) 127 (99%)
clear at Day 2
123 (86%)




at delivery (or Day 42
if later)
AL artemether-lumefantrine; AS artesunate; CI confidence interval; Q quinine; *Chlorproguanil-dapsone has been withdrawn, so the chloroproguanil-dapsone data
are not shown; †median (range) days; {PCR-adjusted, intent-to-treat population; }PCR-adjusted, modified intent-to-treat population.
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adults, mean AUC0!8h 211 ng/ml.h (SD 109)) [21]. This
comparison was made with exposure values from 25 male
Thai malaria patients [34]. However, other reports in non-
pregnant individuals also given the six-dose regimen of AL
[35,36] showed comparable or even lower artemether and
dihydroartemisinin (DHA) exposure values than those
reported in pregnant women in the study by McGready
et al., [21]. These exposure values were measured in healthy
subjects, who are known to exhibit the highest artemether
and lumefantrine absorption and bioavailability when the
drug is given with a standardized meal. Therefore, and be-
cause of the considerably large inter-subject (and inter-
study) variability in the pharmacokinetics of artemether and
lumefantrine, comparisons with historical data should be
done with great caution. Furthermore, despite apparently
lower exposure to artemether and DHA in the study by
McGready et al., [21] all 13 pregnant women treated with
AL were cured. In one woman, P. falciparum infection
reappeared during follow-up (Day 21), but PCR genotyping
confirmed this to be a new infection.
Two of the three efficacy studies of AL during preg-
nancy reported Day 7 lumefantrine plasma levels, a
measure correlated with drug exposure estimates [31]. In
particular, Day 7 lumefantrine plasma levels below
280 ng/ml have been related to the risk of therapeutic
failure [32]. In the Ugandan study that compared AL and
quinine in the second and third trimester of pregnancy
and reported an AL cure rate of 98.2% (PCR-corrected atdelivery (or Day 42 if later)), venous lumefantrine levels
were assessed in 97 women [25]. The median Day 7 lume-
fantrine concentration of 481 ng/ml was similar to the me-
dian concentration of 350 ng/ml previously reported in
healthy adults, but the range of values was larger in the
pregnant population (15–3,246 versus 204–869 ng/ml)
[25,31]. Within this population, there were six women with
recurrent parasitaemia by delivery (or Day 42 if later) (one
recrudescent, two novel, one indeterminate, two non-
falciparum) and five of these women had Day 7 lumefan-
trine levels below 280 ng/ml. However, a third of women
without recrudescent parasitaemia also had a Day 7 lume-
fantrine concentration under 280 ng/ml [25].
A pharmacokinetic extension of the Thai study of AL and
artesunate during the second and third trimesters, which
reported an AL cure rate of 82% (PCR-corrected at delivery
(or Day 42 if later), assessed the capillary plasma lumefan-
trine concentrations in 103 women [37]. This study found
no significant differences in Day 7 lumefantrine concentra-
tion between women with and without recurrent parasit-
aemia, although no treatment failures occurred in women
with lumefantrine concentrations above 550 ng/ml (ap-
proximately 360 ng/ml in venous plasma) [37]. The median
capillary plasma lumefantrine exposure (AUC0!∞) was
472 μg/ml.h (range 119–1261) and the median Day 7 lume-
fantrine concentration was 391 ng/ml (range 126–1600),
approximately equivalent to a median venous plasma con-
centration of 310 ng/ml (range 94–1364) and above the
280 ng/ml threshold predictor of treatment failure [37].
Table 4 Pharmacokinetics of artemether–lumefantrine during pregnancy













of AL in pregnancy using
venous plasma samples
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using capillary plasma










study of AL vs. Q in




plasma samples (n = 97)
481 ng/ml (15–3,246)
AL artemether-lumefantrine; Q quinine;*90% range; †AUC60h!∞.
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Malaria during pregnancy is associated with an increased
risk of maternal anaemia, maternal death, abortion,
premature labour, low birth weight, and neonatal death
[1,7,38]. Control measures recommended in areas of stable
transmission to protect against these outcomes include the
use of preventive strategies and proper case management,
with accurate diagnosis and prompt, effective treatment of
malaria and anaemia [6,9].
The current WHO recommendations for the treatment
of uncomplicated falciparum malaria during pregnancy
are: a locally effective ACT (AL, AS-AQ, AS-MQ or
AS+ SP) in the second and third trimesters of pregnancy,
and quinine plus clindamycin or quinine monotherapy in
the first trimester [11]. These recommendations were
based on available efficacy and safety data for ACT,
which were particularly limited in the first trimester.
This review focused on the safety and efficacy of AL
during pregnancy, since AL has now been widely available
for over ten years in Africa and is used across several conti-
nents. It includes over one thousand reports of AL use in
pregnancy, with 212 in the first trimester [15-17,20,22-27].
However, it should be noted that the literature review
selected English-language publications only, and so there
may be relevant reports or studies that are currently unpub-
lished or published in other languages, that have not been
included in this article.
The reported studies suggest that AL is generally well
tolerated by pregnant women and shows no association
between the use of AL in the second and third trimesters of
pregnancy and an increased risk of spontaneous abortion,
stillbirth or congenital abnormalities when compared with
quinine, SP or artesunate [22,25,26]. In comparison withquinine, which is currently recommended throughout preg-
nancy in some countries, tolerability benefits of AL may
improve treatment compliance [25]. Additionally, quinine
use in late pregnancy is associated with increased risk of
hypoglycaemia [39].
There are fewer available reports on the use of AL by
pregnant women in the first trimester, and 156 of these
were reported in a recent observational study in Zambia
that compared AL and SP [26]. In this study, no differ-
ences were detected between first trimester exposures of
the two drugs in the occurrence of perinatal death, infant
malformation or assessments of infant neurodevelop-
ment. However, seven of 159 foetuses exposed to AL in
the first trimester were miscarried, while there were no
miscarriages of the 135 foetuses exposed to SP and/or
quinine in the first trimester [26]. Although four of the
seven events were linked to confounding factors such as
infection (Table 2), further investigations of the safety of
ACT in the first trimester are recommended.
One factor that may relate to the miscarriages in first
trimester AL exposures is the use of presumptive treat-
ment and the risk of treating women without malaria. In
this study, malaria cases were predominantly diagnosed
based on clinical symptoms without confirmation by
microscopy or RDT [26]. Recent studies in animals and
humans have suggested that the risk of embryotoxicity
from artemisinins may be higher in pregnant women
who do not have malaria than those with malaria, as
healthy volunteers taking artemisinins have shown
greater decreases in reticulocyte count, a possible marker
for embryotoxicity, than adults treated for malaria [40].
Another relevant risk factor for miscarriage is malaria
infection in the first trimester of pregnancy. Analysis of
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between 1986 and 2010 compared the outcomes of 945
confirmed cases of malaria in the first trimester of preg-
nancy with 16,668 pregnancies without a malaria infec-
tion, and showed that malaria infection in the first
trimester was associated with increased risk of miscar-
riage, and this risk was similar in women treated with
chloroquine, quinine and artesunate [41].
The available studies suggest that the use of AL in the
second and third trimesters of pregnancy is not associated
with adverse outcomes. However, to detect any rare adverse
events, which may not become apparent in clinical studies,
it is important to monitor pregnancy outcomes following all
exposures of pregnant women to anti-malarial treatments.
This will increase the pool of available safety data for assess-
ment of which treatments are most appropriate for use in
pregnancy. There have been calls for anti-malarial preg-
nancy exposure registries for large-scale data collection
[42], and recently the design, feasibility and implementation
of an Electronic Perinatal Record system was successfully
tested in Lusaka, Zambia [43].
The efficacy of AL has been studied in the second and
third trimesters of pregnancy in randomized controlled
trials. Studies in Uganda revealed higher efficacy than
reports from Thailand [22,23,25]. The efficacy of AL during
pregnancy in the two Ugandan trials, but not the Thai trial,
is similar to the results from studies in adults and children
that have consistently reported AL efficacy of over 95%
[44]. The reasons for these differences in cure rate are
currently unclear, but several explanations have been
suggested. The study in Thailand compared AL and artesu-
nate monotherapy in pregnant women. In this study, fever
and parasite clearance were rapid and similar after both
treatments. PCR-corrected parasitological cure rates at de-
livery (or Day 42 if later) were 82.0% for AL and 89.2% for
artesunate. Fewer than half of the patients had primary
infections at baseline, and for patients with recrudescent
infections at baseline, the cure rate with AL was signifi-
cantly lower than that with artesunate. However, for
patients with primary infections or new infections at base-
line following a previous episode, cure rates for the two
treatments were similar. This is consistent with a previous
report of reduced susceptibility of recrudescent infections
to quinine, mefloquine and lumefantrine in this area,
suggesting that the relatively lower cure rate may be due to
relatively resistant parasites under such circumstances [22].
Piola and colleagues proposed that differences in the level
of malaria immunity between the sites of the Ugandan and
Thai trials could explain the different efficacies of AL in
pregnant women, a plausible interpretation given the
marked differences in the intensity of malaria transmission.
The differences in cure rate could also be explained by the
emergence of parasite resistance to artemisinins or lumefan-
trine at the Thai study site (Thai-Burmese border).There have also been suggestions that changes in
the pharmacokinetics of artemether and lumefantrine
during pregnancy may influence the efficacy of AL
[21,22,25,29,30,37]. Small changes in AL exposure
during pregnancy have been reported [21,25], but
these results should be viewed with caution as they
involve inter-trial comparisons, small populations, high
inter-individual variation in plasma levels and the average
plasma levels reported are comparable with data from
non-pregnant adults [21,22,25,31-37,45]. Approximately
one third of women in the Ugandan and Thai studies had
a Day 7 lumefantrine concentration below 280 ng/ml,
suggesting that lumefantrine concentration is unlikely to
account for the reported differences in AL efficacy
between the studies [22,25]. In Tarning et al., no signifi-
cant differences (p= 0.26) in predicted Day 7 lumefantrine
levels were detected between women with and without
parasitaemia receiving AL in Thailand. However, it is of
note that the predicted median Day 7 lumefantrine con-
centration in this pregnant population was reported to be
lower than previous studies in children and non-pregnant
adults in Thailand, Cambodia and the Lao People’s
Democratic Republic [37]. These analyses, together with re-
cent results suggesting that DHA clearance may be approxi-
mately 42% higher in pregnant women [46,47], support the
view that further study of the pharmacokinetics of AL in
pregnancy would be of benefit to help maintain confidence
in dosing regimens and ensure that pregnant women re-
ceive an appropriate treatment regimen. The Malaria in
Pregnancy consortium has recently conducted a trial in
Uganda comparing the AL pharmacokinetics in pregnant
and matched non-pregnant women, and the data from this
study are eagerly awaited [48].
Co-morbidities and concomitant medications may also
impact on the pharmacokinetics of anti-malarial treatments
in children, adults and in pregnant women. There are
several reports that HIV infection may influence the out-
come of anti-malarial treatments, although the reported
effects differ between the studies [49]. One small study in
Ethiopia reported reduced clearance of P. falciparum by
artemisinin in patients with HIV [50]. The potential for
drug–drug interactions between both HIV and tuberculosis
treatments and anti-malarials has been identified, but only
limited pharmacokinetic data are available for some
HIV treatments and there are currently no published
data available for tuberculosis treatments. The effect
of lopinavir/ritonavir (a protease inhibitor combination
for treating HIV) on the pharmacokinetics of AL was
tested in 13 healthy non-HIV infected adults. This
study showed a two- to three-fold increase in lume-
fantrine exposure (AUC) and small decreases in arte-
mether and DHA exposure (AUC and Cmax) when AL
and lopinavir/ritonavir were co-administered [51]. Fur-
ther studies are required to determine whether these
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malarials in the general population and during pregnancy.
Guidelines for the case management of malaria vary
between countries, including the guidelines for treatment
at different stages of pregnancy. Not all countries with
endemic malaria have adopted the WHO recommenda-
tion to use ACT for uncomplicated falciparum malaria
during the second and third trimesters of pregnancy.
Reasons for recommending alternative treatments such
as quinine or SP are likely to differ between countries
according to local study data and economic and political
considerations. South Africa currently recommends
quinine plus clindamycin for the treatment of uncompli-
cated malaria in pregnancy due to concerns for foetal
safety, based on animal studies, and a report of subopti-
mal lumefantrine absorption during pregnancy [52]. In
addition, ACT is not currently recommended during
pregnancy in Ethiopia, as local studies were considered
necessary to identify those most suitable for use. As part
of the President’s Malaria Initiative, there are plans to
revise the existing treatment guidelines, and the use of
ACT in pregnancy will be considered [53].
The recent publication of new safety data and the results
from ongoing studies may impact current national policies.
Full publication of a recent study of the safety of DHA-PPQ
in the second and third trimester is eagerly awaited. Avail-
able data suggest that, in a population of 1,160 pregnant
women, there was no increased risk of congenital abnor-
malities or stillbirths, and so DHA-PPQ may also be a suit-
able ACT for use in pregnancy [54]. Another trial is
currently recruiting subjects in Burkina Faso, Ghana,
Malawi and Zambia, with the aim of evaluating the efficacy
and safety of four types of ACT (AL, AS-AQ, AS-MQ, and
DHA-PPQ) for the treatment of pregnant women with P.
falciparum malaria (PREGACT study: Safe and Efficacious
Artemisinin-based Combination Treatments for African
Pregnant Women With Malaria (Clinical Trials identifier
NCT00852423)) expected to end in July 2014. There is also
a similar trial ongoing in Brazil (Clinical Trials identifier
NCT01082731), which is estimated to end in August 2012,
and a pharmacovigilance study in Africa (Clinical Trials
identifier NCT01232530) expected to end in October 2013.
Conclusions
The use of AL for the treatment of uncomplicated P.
falciparum malaria in pregnancy is supported by a large
body of evidence. In the second and third trimesters, the
available safety data support the use of AL, but further
studies to assess the safety of AL in the first trimester are
recommended. Since quinine with clindamycin is the
currently recommended treatment during the first trimes-
ter, studies comparing the safety of AL versus quinine and
clindamycin may be most appropriate. AL may be prefer-
able to quinine in the second and third trimesters as ALefficacy is non-inferior to quinine, but is associated
with fewer adverse events. There are some reports
that suggest there may be a change in AL pharmaco-
kinetics in pregnancy, although the impact on efficacy
and safety needs to be studied further, especially since
the majority of studies in pregnancy report high cure
rates and adequate tolerability. Direct comparisons of
drug levels and efficacy between pregnant and non-
pregnant women are needed to separate any pharma-
cokinetic change in pregnancy from other factors such
as the type of infection (novel or recrudescent), back-
ground immunity and parasite sensitivity.
The WHO recommendation for the use of appropriate
ACT in the second and third trimesters of pregnancy is
supported by the currently available data and the univer-
sal implementation of these recommendations through-
out the African WHO region should occur. There is also
need for further safety studies on the outcomes of ACT
use during pregnancy and in particular, comparisons
between the efficacy and safety of ACT and quinine with
clindamycin during the first trimester.Additional files
Additional file 1: Ovid search strategy. Ovid was used to search the
EMBASE, MEDLINE, BIOSIS (included In-Process and Other Non-indexed
Citations, Daily Update) and Cochrane (included Cochrane Database of
Systematic Reviews, APC Journal Club, Database of Abstracts of Reviews
of Effects, Cochrane Central Register of Controlled Trials, Cochrane
Methodology Register, Health Technology Assessment, NHS Economic
Evaluation Database) databases between 1948 and 2011. Six queries were
performed using the search terms shown. *Search for the term shown
with or without any number of additional letters; ?Search for the term
shown with or without one additional letter.
Additional file 2: Results of literature search: Number of references
identified for each query and database. EMBASE, MEDLINE, BIOSIS and
Cochrane were searched on 16 December, 2011. Malaria in Pregnancy
consortium library, Clinicaltrials.gov and WHO ICTRP were searched on 8
December, 2011 and TrialTrove was searched on 14 December, 2011.
ICTRP, International Clinical Trials Registry Platform.
Additional file 3: 400 unique references recovered in the literature
search.
Additional file 4: Publications reporting on the safety, efficacy and
pharmacokinetics of artemether and artemether-lumefantrine in
pregnancy, including the number of exposures during pregnancy.
Sixteen articles were identified by the literature search, all reporting on
pregnancies exposed to artemether or artemether-lumefantrine. The
number of pregnancies exposed to artemether or artemether-
lumefantrine are reported, and it is noted where exposures have been
previously reported. AL, artemether-lumefantrine; AE, adverse events; SAE,
serious adverse events; SP, sulphadoxine-pyrimethamine; ACT, artemisinin-
based combination therapies; †National treatment policy is quinine
throughout pregnancy [55-57]; †National treatment policy is quinine in
the first trimester and ACT in the second and third trimesters of
pregnancy [55,58,59]; }National treatment policy is quinine in the first
trimester and SP in the second and third trimesters of pregnancy; Benin,†
Burkina Faso,† Cameroon,† DRC,† Gabon,† Mozambique,† Mali,† Thailand,†
Ghana,{ Kenya,{ Malawi,{ Nigeria,{ Sudan,{ Tanzania,{ Uganda,{ Zambia,}
[26,55,57-59]; #McGready et al., 2001 [17] includes all of the artemether
exposures reported across three publications. To avoid duplication of
pregnancy exposures the other two reports have not been included
[18,19]; }Included women with a pregnancy in the last
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pregnancies were excluded; ††Mali,† Mozambique,† Thailand,† Kenya,{
Nigeria,{ Sudan,{ Tanzania,{ Zambia} [26,55,57,59]; {{National treatment
policy is quinine/AL [60]. Wang, 1989 [20], Sowunmi et al., 1998 [15],
McGready et al., 2001 [17], Adam et al., 2004 [16], McGready et al., 2006
[21], Dellicour et al., 2007 [14], McGready et al., 2008 [22], Kaye et al., 2008
[23], Orton et al., 2008 [61], Adam et al., 2009 [24], Tarning et al., 2009 [37],
Piola et al., 2010 [25], Manyando et al., 2010 [26], McGready et al., 2011
[29], Sangaré et al., 2011 [27], Wilby and Ensom, 2011 [30].
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